Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418823 | 0.98 | HRH3 (0.48) | HRH3LTA4HKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL7110089 | 0.87 | HRH3 (0.55) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL8361918 | 0.85 | HRH3 (0.60) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL10914988 | 0.85 | HRH3 (0.52) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7887990 | 0.85 | HRH3 (0.60) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL24059343 | 0.85 | HRH3 (0.60) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL9544504 | 0.85 | HRH3 (0.52) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL9542003 | 0.85 | HRH3 (0.52) | HRH3LTA4HKDM4EHTTSMN1; SMN2 | |
| SCHEMBL9544441 | 0.82 | HRH3 (0.57) | HRH3LTA4HKDM4EHTTKMT2A | |
| SCHEMBL9542084 | 0.82 | HRH3 (0.57) | HRH3LTA4HKDM4EHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | claimed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | claimed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | claimed |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | claimed |
| EP-1575943-A1 | 3-CYANO-QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | claimed |
| WO-2004041811-A1 | 3-CYANO-QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
| EP-0576915-B1 | cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | SIGMA TAU IND FARMACEUTI (IT) | 1997-04-16 | — | — | EP | claimed |
| EP-0590272-B1 | 17B-Aryl and 17B-heterocyclyl-5-beta,14-beta-andostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | SIGMA TAU IND FARMACEUTI (IT) | 1997-01-02 | — | — | EP | claimed |
| EP-0590271-B1 | 17-Aryl and 17-heterocyclyl-14beta-5alpha-androstane, androstene and androstadiene derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | SIGMA TAU IND FARMACEUTI (IT) | 1996-11-27 | — | — | EP | claimed |
| EP-0590272-A2 | 17B-Aryl and 17B-heterocyclyl-5-beta,14-beta-andostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-04-06 | — | — | EP | claimed |
| EP-0590271-A2 | 17-Aryl and 17-heterocyclyl-14beta-5alpha-androstane, androstene and androstadiene derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-04-06 | — | — | EP | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| EP-0590272-A2 | 17B-Aryl and 17B-heterocyclyl-5-beta,14-beta-andostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
| EP-0590271-A2 | 17-Aryl and 17-heterocyclyl-14beta-5alpha-androstane, androstene and androstadiene derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | HRH3 980/4885LTA4H 3033/4885KDM4E 660/4885 |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | HRH3 961/4885LTA4H 2785/4885KDM4E 1779/4885 |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | HRH3 1491/4885LTA4H 3216/4885KDM4E 1305/4885 |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | HRH3 961/4885LTA4H 2785/4885KDM4E 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.